Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy
Authors' conclusion
The 2026 dyslipidemia guideline substantially expands the US population recommended for primary prevention statin therapy, predominantly in lower-risk individuals.
Study context
- Population
- Nonpregnant US adults aged 30–79 years without known atherosclerotic cardiovascular disease (ASCVD), NHANES 2017–2023representative of 154.5 million US adults
- Participants
- 4,366 adults
- Exposure
- 2026 vs 2018 lipid guideline statin eligibility
- Outcome
- Changes in eligibility for primary prevention statin therapy, 2026 vs 2018 lipid guidelines
Methodological detailsnationally representative, weighted sample
- Nationally representative
- Weighted sample
Main finding
As reported in the abstract
Statin eligibility under 2026 guideline
Statin eligible under 2026 guideline: 87.5 million
56.6%
95% CI 54.2%–58.9%
Newly statin eligible: 21.5 million
13.9%
95% CI 12.5%–15.5%
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Newly statin eligible | Previously eligible |
|---|---|---|
| Mean estimated 10-year ASCVD risk | 3.1% (95% CI 2.7%–3.5%) | 6.1% (95% CI 5.8%–6.4%) |
Statin eligibility by age
- Aged 70–79 years
- More than 93%
- Aged 60–69 years
- 85%
- Aged 30–39 years
- 11%
Baseline categories
- Untreated LDL-C <70 mg/dL
- 5.5% (95% CI, 4.7%-6.6%)
- Currently taking statins
- 17.8% (95% CI, 16.3%-19.5%)
- Eligible independent of risk estimation (LDL-C ≥190 mg/dL, DM or CKD)
- 8.6% (95% CI, 7.6%-9.8%)
- Risk estimation to guide statin decisions
- 68.0% (95% CI, 65.9%-70.0%)
Original publication
Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy. JAMA. Published 18 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →